Identification of a bone morphogenetic protein type 2 receptor neutralizing antibody

Originally appearing in BMC Research Notes as an open access article under the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).

The bone morphogenetic protein (BMP) signaling pathway comprises the largest subdivision of the transforming growth factor (TGFβ) superfamily. BMP signaling plays essential roles in both embryonic development and postnatal tissue homeostasis. Dysregulated BMP signaling underlies human pathologies ranging from pulmonary arterial hypertension to heterotopic ossification. Thus, understanding the basic mechanisms and regulation of BMP signaling may yield translational opportunities. Unfortunately, limited tools are available to evaluate this pathway, and genetic approaches are frequently confounded by developmental requirements or ability of pathway components to compensate for one another. Specific inhibitors for type 2 receptors are poorly represented. Thus, we sought to identify and validate an antibody that neutralizes the ligand-binding function of BMP receptor type 2 (BMPR2) extracellular domain (ECD).

Ruthann E. Gorrell, Madeline H. Totten share equal contribution to this work.

Creator

• Hum, Julia M.
• Totten, Madeline
• Gorrell, Ruthann
• Schoerning, Laura
• Newby, Jordan B.
• Lowery, Jonathan W.
• Geyman, Logan J.
• Lawless, Warren

Identifier

• 10.1186/s13104-019-4367-0

Mot-clé

• Bone Morphogenetic Protein
• Osteopathic Medicine

Date created

• 6-11-2019

Related URL

•  http://creativecommons.org/licenses/by/4.0/

Resource type

• Article

Source

• BMC Research Notes (Vol.12, no.1)

Rights statement

• http://rightsstatements.org/vocab/InC/1.0/